Rainier Therapeutics, Inc.

The frenzied flow of funds into biopharma venture capital has resulted in a lot of big bets, but recent small financings are encouraging as cash is harder to come by at the earliest stages of drug dis

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bio

Founded in 2014 with $40m in the bank, Therachon AG is developing TA-46 for achondroplasia, a molecule that CEO Luca Santarelli said the company evolved from an "academic prototype," created by founde

La Jolla Pharmaceutical Co. with its $125m stock sale led a recent spate of secondary offerings by biopharmaceutical firms as companies attempt to fortify their cash balances before the "Trump bump"